cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
Joseph A. Francisco(Seagen (United States)), Alan F. Wahl(Seagen (United States)), Brian E. Toki(Seagen (United States)), Damon L. Meyer(Seagen (United States)), Che‐Leung Law(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Ron L DeBlanc(Seagen (United States)), Kristine A. Gordon(Seagen (United States)), Dana F. Chace(Seagen (United States)), Bruce Mixan(Seagen (United States)), Starr X. Rejniak(Seagen (United States)), Peter D. Senter(Seagen (United States)), Svetlana O. Doronina(Seagen (United States)), Clay B. Siegall(Bristol-Myers Squibb (United States)), Kerry Klussman(Seagen (United States))
Cited by 918
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Antibody-Drug Conjugates in Cancer Therapy
|Annual Review of Medicine|2012|763